Search for a trial

Less injections by androgen scrutinisation

The primary objective of this study is to determine the possibility to extend the dosing interval of goserelin 10.8 mg with a testosterone-based dosing regimen compared to regular treatment with 3-monthly based goserelin 10.8 mg injections. This…

A PHASE Ib/II STUDY OF IPATASERTIB (GDC-0068) OR APITILISIB (GDC-0980) WITH ABIRATERONE ACETATE VERSUS ABIRATERONE ACETATE IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL-BASED CHEMOTHERAPY

PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…

A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy

The primary objective is to show superiority of treatment with DCVAC/PCa in addition to Standard of Care chemotherapy (docetaxel plus prednisone) over placebo in addition to Standard of Care chemotherapy (docetaxel plus prednisone) in men with mCRPC…

Towards optimal treatment for high risk prostate cancer; stereotactic pelvic radiotherapy with focal boost to the primary tumor

Determine the safety (oncologica! outcome and toxicity) of an comprehensive treatment combining recent advances in the treatmentof high risk prostate cancer.

A pilot feasibility study of Dose dE-eScalaTion IN prostATe radIOtherapy with empty bladder usiNg the
MRL - DESTINATION 1B(ladder)

To develop a 5 fraction de-escalated dose SBRT protocol potentially capable of reducing side effects intended for prostate cancer patients with empty bladder